Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Top Cited Papers
Open Access
- 10 October 2013
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 122 (15), 2539-2549
- https://doi.org/10.1182/blood-2013-06-507947
Abstract
Given its critical role in T-cell signaling, interleukin-2–inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of ITK subverts Th2 immunity, thereby potentiating Th1-based immune responses. While small-molecule ITK inhibitors have been identified, none have demonstrated clinical utility. Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancies. Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK. Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib. Using ibrutinib clinical trial samples along with well-characterized neoplastic (chronic lymphocytic leukemia), parasitic infection (Leishmania major), and infectious disease (Listeria monocytogenes) models, we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility. This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749.Keywords
This publication has 42 references indexed in Scilit:
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesJournal of Clinical Oncology, 2013
- Itk inhibitors: a patent reviewExpert Opinion on Therapeutic Patents, 2010
- Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinasesProtein Science, 2010
- Circumventing Immune Tolerance Through Epigenetic ModificationCurrent Pharmaceutical Design, 2010
- Differential requirements for IL‐4/STAT6 signalling in CD4 T‐cell fate determination and Th2‐immune effector responsesImmunology & Cell Biology, 2009
- T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)Blood, 2009
- The Immune System and CancerCancer Biotherapy & Radiopharmaceuticals, 2009
- Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen-presenting cell functionClinical and Experimental Immunology, 2003
- Abnormal T-cell Function in B-cell Chronic Lymphocytic LeukaemiaLeukemia & Lymphoma, 2003
- Impaired NFATc Translocation and Failure of Th2 Development in Itk-Deficient CD4+ T CellsImmunity, 1999